Spot by NetApp Delivers Cloud Desktop-as-a-Service Solution for Service Providers, Enterprises and Today’s Distributed Workforce
17.5.2022 15:00:00 EEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the general availability of Spot PC, the managed cloud Desktop-as-a-Service (DaaS) solution — with security, automation, observability and optimization designed for the public cloud and for the needs of today’s remote and distributed working environments.
Available today, Spot PC provides Managed Service Providers (MSPs) and their customers with a cloud desktop solution optimized for security, privacy and infrastructure efficiency, with predictable pricing to reduce overall support burdens and allow existing staff to deliver and support many more desktops, increasing profitability.
With the rapid acceleration of hybrid work environments, organizations have been compelled to evolve their IT infrastructure to support remote work environments, building distributed teams, and enabling hybrid offices while navigating supply chain issues and cyber security threats.
But the most common solutions available to deliver remote desktops, based on traditional virtual desktop infrastructure (VDI) were never designed for the public cloud and therefore require significant effort for administration, management and troubleshooting. As a result, today’s remote desktop offerings come with significant operations burdens, can be time consuming and complex to set up, migrate to, and manage, and are expensive to deploy and operate.
“Service providers and enterprises today require the right tools and solutions that are built for the cloud for optimal efficiency of their resources,” said Anthony Lye, Executive Vice President of Public Cloud Services at NetApp. “With Spot PC, we’re equipping MSPs and enterprises to bring differentiated, profitable cloud desktop solutions to market to meet growing demand from their customers and enabling them to deliver flexible, secure and fit-for-purpose remote work experiences to a variety of users across multiple locations and regions.”
Spot PC delivers a comprehensive as-a-service solution to these challenges, enabling MSPs and enterprises to provide secure, reliable, and fully optimized cloud desktops to support a broad range of needs.
Spot PC provides MSPs and enterprises with the ability to:
- Deliver cloud desktops with speed, flexibility and agility across multiple locations and regions to support a wide range of tasks for knowledge and technical computing users
- Ensure that cloud desktop environments meet security, availability and performance requirements without overburdening IT staff
- Provide predictable cost structure using patent-pending AI and machine learning automated optimization
“We are really excited for Spot PC and the benefits and automation it will provide us and our clients,” said Derek Anderson, President at Biztek Solutions. “We see Spot PC as the go to solution for secure, cloud hosted desktops that will enable businesses to adopt remote and hybrid work environments that easily scale with their business.”
“Working with NetApp has meant that Cloud PC as a Service has become an exciting prospect for our clients to enjoy Spot PC, combined with complete support for the virtual desktop and the office suite that our clients use,” said Peter Beglan, CEO at Cloud PC Ltd & HyCloud Ltd. “We are so confident that this combined virtual desktop solution will be eagerly received in the UK that we have already made plans to start offering Cloud PC as a Service within the European marketplace.”
Spot PC is available today, direct from NetApp for enterprises and service providers with a fixed pricing structure per user per month.
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005461/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom